The invention relates to methods for detecting the oncogenic condition of cells, including step where the amount of the OCDO compound in said cells is measured, and to the uses thereof. The invention further relates to OCDO inhibitors for use in methods for treating cancer.

Compositions including an odd chain fatty acid, and salts and derivatives thereof, and methods for metabolic syndrome treatment and prophylaxis are provided, including compositions and methods for treating diabetes, obesity, hyperferritinemia, elevated insulin, glucose intolerance, dyslipidemia and related conditions. Methods for the diagnosis and monitoring of metabolic syndrome are also provided.

The present invention relates to use of a microRNA or an inhibitor thereof, and specifically, the present invention relates to use of a microRNA or an inhibitor thereof in preparing a medicament for regulating lipid metabolism or preparing a medicament for preventing or treating a disease related to lipid metabolism. The microRNA is one or more of the following: miRNA-96, miRNA-185, and miRNA-223. The present invention also relates to use of the microRNA or the inhibitor thereof in regulating the expression level of a protein related to lipid metabolism. The present invention also relates to a composition comprising the microRNA or the inhibitor thereof. The microRNA or the inhibitor thereof in the present invention can be used as a pharmaceutical component, and can be applied in preventing or treating a disease caused by lipid metabolism disorders such as hyperlipidemia, atherosclerosis, coronary heart disease or other diseases.

The invention provides novel immunological adjuvants and methods for identification of such adjuvants. The invention further provides methods and compositions for eliciting an immune response to an immunogen using the novel adjuvants. The adjuvants can be employed with any suitable immunogen, including proteins, peptides, lipids, and carbohydrates. The immunogen can be derived from a virus, a cancer, or a diseased cell. The elicited immune response can be cellular, humoral, or both.

A method for treating and/or diagnosing pain and the source or type of pain, shock, and/or inflammatory conditions in a subject. A method of using a therapeutically effective amount of a DNA or RNA aptamer that shows high affinity for OLAMs to at least partially treat pain, shock, and/or inflammatory conditions in a subject. The DNA or RNA aptamer that shows high affinity for OLAMs may be coupled to a plasma protein binding compound or a pharmacologically active agent. A method of treating and or diagnosing pain, shock, and/or inflammatory conditions in a subject may include inactivating or preventing at least one linoleic acid metabolite to treat certain conditions (e.g., pain, shock, and/or inflammation) using a DNA or RNA aptamer that shows high affinity for OLAMs.

A lipophilic anchor includes a conjugation domain linked via a linker domain to an anchor domain having a plurality of hydrophobic tails. This lipophilic anchor allows deposition of at least one lipophilic target molecule with affinity for the anchor domain on a hydrophilic surface conjugated to the conjugation domain. The lipophilic target molecule coated hydrophilic substrate has the conjugation domain of the lipophilic anchor bound to the hydrophilic surface of a substrate and lipophilic target molecules are non-covalently bound to the anchor domain.

A method is disclosed to capture and purify extracellular vesicles from biofluids via lipid affinity-based capture. The EVTRAP (Extracellular Vesicles Total Recovery And Purification) method enables capture of EVs onto modified beads. The EVTRAP method results in fast and reproducible capture and isolation of EVs with greater than 90% recovery yields.

Methods for detecting risks for and/or causes of metabolic syndrome or hyperferritinemia in accordance with several embodiments can include the step of measuring the level of heptadecanoic acid in a blood sample of a subject. The methods of several embodiments can further include the step of deeming the subject as having or being at risk of metabolic syndrome if the amount of heptadecanoic acid is below 0.4% of all fatty acids in the sera or plasma. The methods for treating metabolic syndrome or hyperferritinemia according to several embodiments can also include the step of administering a daily dose of heptadecanoic acid to a subject suffering from metabolic syndrome or hyperferritinemia for a period of time from three weeks to twenty-four weeks, wherein the minimum daily dose comprises about 3 mg per lb (or 6 mg per kg) of body weight.

An unseen benefit indicator kit containing a vitamin, mineral, supplement product, a first biomarker test, and a final biomarker test. The kit provides an unseen benefit indicator that allows users to see health benefits while taking the vitamin, mineral, supplement product.

An in vitro method for assessing whether a subject is at risk to develop or is suffering from fatty liver disease comprising: (a) assaying a sample from said subject to determine a concentration of at least one fatty liver biomarker from Group E; (b) assaying a sample from said subject to determine a concentration of at least one fatty liver biomarker from Group F; and (c) determining that the subject is suffering from or is at an increased risk of developing fatty liver disease, if said sample contains an increased combination biomarker value of the at least one fatty liver biomarker from Group E and the at least one fatty liver biomarker from Group F, when compared to a control.